Cargando…
Urodynamic outcomes after pelvic nerve-sparing radical hysterectomy with or without neoadjuvant chemotherapy
OBJECTIVE: Our purposes of this study were to characterize a group of bulky cervical cancer patients who underwent a nerve sparing radical hysterectomy (NSRH) with or without neoadjuvant chemotherapy (NAC), to compare surgical outcomes and the preservation of bladder function, and to compare prognos...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718266/ https://www.ncbi.nlm.nih.gov/pubmed/31497250 http://dx.doi.org/10.18632/oncotarget.27147 |
_version_ | 1783447706334658560 |
---|---|
author | Tsunetoh, Satoshi Terai, Yoshito Takai, Masaaki Fujiwara, Satoe Tanaka, Yoshimichi Tanaka, Tomohito Sasaki, Hiroshi Ibuki, Naokazu Ubai, Takanobu Yamamoto, Kazuhiro Azuma, Haruhito Ohmichi, Masahide |
author_facet | Tsunetoh, Satoshi Terai, Yoshito Takai, Masaaki Fujiwara, Satoe Tanaka, Yoshimichi Tanaka, Tomohito Sasaki, Hiroshi Ibuki, Naokazu Ubai, Takanobu Yamamoto, Kazuhiro Azuma, Haruhito Ohmichi, Masahide |
author_sort | Tsunetoh, Satoshi |
collection | PubMed |
description | OBJECTIVE: Our purposes of this study were to characterize a group of bulky cervical cancer patients who underwent a nerve sparing radical hysterectomy (NSRH) with or without neoadjuvant chemotherapy (NAC), to compare surgical outcomes and the preservation of bladder function, and to compare prognoses. RESULTS: Fifty-three patients had NSRH without NAC (Group A), and 33 patients had NSRH after NAC (Group B). With regard to prognostic factors, there was only a significant difference between both groups with regard to lymph node metastasis (15% vs 42%, P = 0.01). Moreover, bladder function in Group B patients improved to the same extent as the preoperative rate three months postoperatively. These data were similar to the results in Group A. With regard to overall survival, the 5-year survival rate was 98.1% (95% confidence interval (CI) 87.8–99.7) in Group A and 86.7% (95% CI 71.7–96.7) in Group B (P > 0.1). METHODS: We retrospectively identified 86 patients with cervical cancer who underwent NSRH at Osaka Medical College from May 2009 to November 2016. NAC was performed via balloon occluded arterial infusion. We extracted data on the patient's stage of progress, tumor volume, histological subtype, bleeding volume, urodynamic study results, and postoperative complications. The data were divided into two groups - those patients who received NAC and those who did not - and then compared. CONCLUSIONS: According to our analysis, NSRH surgery after NAC via balloon occluded arterial infusion brings beneficial results to patients with bulky IB2 to IIB cervical cancers. |
format | Online Article Text |
id | pubmed-6718266 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-67182662019-09-06 Urodynamic outcomes after pelvic nerve-sparing radical hysterectomy with or without neoadjuvant chemotherapy Tsunetoh, Satoshi Terai, Yoshito Takai, Masaaki Fujiwara, Satoe Tanaka, Yoshimichi Tanaka, Tomohito Sasaki, Hiroshi Ibuki, Naokazu Ubai, Takanobu Yamamoto, Kazuhiro Azuma, Haruhito Ohmichi, Masahide Oncotarget Research Paper OBJECTIVE: Our purposes of this study were to characterize a group of bulky cervical cancer patients who underwent a nerve sparing radical hysterectomy (NSRH) with or without neoadjuvant chemotherapy (NAC), to compare surgical outcomes and the preservation of bladder function, and to compare prognoses. RESULTS: Fifty-three patients had NSRH without NAC (Group A), and 33 patients had NSRH after NAC (Group B). With regard to prognostic factors, there was only a significant difference between both groups with regard to lymph node metastasis (15% vs 42%, P = 0.01). Moreover, bladder function in Group B patients improved to the same extent as the preoperative rate three months postoperatively. These data were similar to the results in Group A. With regard to overall survival, the 5-year survival rate was 98.1% (95% confidence interval (CI) 87.8–99.7) in Group A and 86.7% (95% CI 71.7–96.7) in Group B (P > 0.1). METHODS: We retrospectively identified 86 patients with cervical cancer who underwent NSRH at Osaka Medical College from May 2009 to November 2016. NAC was performed via balloon occluded arterial infusion. We extracted data on the patient's stage of progress, tumor volume, histological subtype, bleeding volume, urodynamic study results, and postoperative complications. The data were divided into two groups - those patients who received NAC and those who did not - and then compared. CONCLUSIONS: According to our analysis, NSRH surgery after NAC via balloon occluded arterial infusion brings beneficial results to patients with bulky IB2 to IIB cervical cancers. Impact Journals LLC 2019-08-27 /pmc/articles/PMC6718266/ /pubmed/31497250 http://dx.doi.org/10.18632/oncotarget.27147 Text en Copyright: © 2019 Tsunetoh et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Tsunetoh, Satoshi Terai, Yoshito Takai, Masaaki Fujiwara, Satoe Tanaka, Yoshimichi Tanaka, Tomohito Sasaki, Hiroshi Ibuki, Naokazu Ubai, Takanobu Yamamoto, Kazuhiro Azuma, Haruhito Ohmichi, Masahide Urodynamic outcomes after pelvic nerve-sparing radical hysterectomy with or without neoadjuvant chemotherapy |
title | Urodynamic outcomes after pelvic nerve-sparing radical hysterectomy with or without neoadjuvant chemotherapy |
title_full | Urodynamic outcomes after pelvic nerve-sparing radical hysterectomy with or without neoadjuvant chemotherapy |
title_fullStr | Urodynamic outcomes after pelvic nerve-sparing radical hysterectomy with or without neoadjuvant chemotherapy |
title_full_unstemmed | Urodynamic outcomes after pelvic nerve-sparing radical hysterectomy with or without neoadjuvant chemotherapy |
title_short | Urodynamic outcomes after pelvic nerve-sparing radical hysterectomy with or without neoadjuvant chemotherapy |
title_sort | urodynamic outcomes after pelvic nerve-sparing radical hysterectomy with or without neoadjuvant chemotherapy |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718266/ https://www.ncbi.nlm.nih.gov/pubmed/31497250 http://dx.doi.org/10.18632/oncotarget.27147 |
work_keys_str_mv | AT tsunetohsatoshi urodynamicoutcomesafterpelvicnervesparingradicalhysterectomywithorwithoutneoadjuvantchemotherapy AT teraiyoshito urodynamicoutcomesafterpelvicnervesparingradicalhysterectomywithorwithoutneoadjuvantchemotherapy AT takaimasaaki urodynamicoutcomesafterpelvicnervesparingradicalhysterectomywithorwithoutneoadjuvantchemotherapy AT fujiwarasatoe urodynamicoutcomesafterpelvicnervesparingradicalhysterectomywithorwithoutneoadjuvantchemotherapy AT tanakayoshimichi urodynamicoutcomesafterpelvicnervesparingradicalhysterectomywithorwithoutneoadjuvantchemotherapy AT tanakatomohito urodynamicoutcomesafterpelvicnervesparingradicalhysterectomywithorwithoutneoadjuvantchemotherapy AT sasakihiroshi urodynamicoutcomesafterpelvicnervesparingradicalhysterectomywithorwithoutneoadjuvantchemotherapy AT ibukinaokazu urodynamicoutcomesafterpelvicnervesparingradicalhysterectomywithorwithoutneoadjuvantchemotherapy AT ubaitakanobu urodynamicoutcomesafterpelvicnervesparingradicalhysterectomywithorwithoutneoadjuvantchemotherapy AT yamamotokazuhiro urodynamicoutcomesafterpelvicnervesparingradicalhysterectomywithorwithoutneoadjuvantchemotherapy AT azumaharuhito urodynamicoutcomesafterpelvicnervesparingradicalhysterectomywithorwithoutneoadjuvantchemotherapy AT ohmichimasahide urodynamicoutcomesafterpelvicnervesparingradicalhysterectomywithorwithoutneoadjuvantchemotherapy |